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several studies provide evidence that performing a restaging tur decreases errors in staging, with potentially positive effects on further disease management in patients with nonmuscle-invasive bladder cancer. 7 recent studies 8, 9 have also shown that a restaging tur provides a possible therapeutic benefit and better local tumor control for patients with t1 bladder tumors, as well as an improvement in shortterm response to intravesical therapy. 8 a 53% recurrence rate was reported among patients with nonmuscle-invasive disease who did not undergo a restaging tur, compared with a rate of 38% in those who did. 9 of 132 patients who received bacillus Calmette-Guérin after a single tur, recurrent tumor at first follow-up cystoscopy was seen in 75 patients (57%), and progression in 45 (34%), compared with 65 of 215 patients (29%) with recurrent tumor, and 16 (7%) with cancer progression following a restaging tur. Divrik and colleagues 10 report similar results in a cohort of patients randomized to intra vesical mitomycin C with or without a restaging tur-the recurrence-free survival rate at 3 years was 69% in patients who were treated after a restaging tur versus 37% in patients who received mitomycin C after a single tur. Furthermore, a second tur provides additional pathologic information that may direct future treatment. Herr et al. 7 reported that 92 of 352 patients (26%) presenting with t1 bladder cancer on initial tur had residual t1 cancer on restaging tur, and of these 92 patients, 75 (82%) progressed to muscle invasion within 5 years compared with 49 (19%) of the 260 patients in whom no, or non-t1, tumor was detected on restaging tur.
there is considerable clinical evidence that restaging tur can reduce the risk of bladder cancer recurrence and progression, [8] [9] [10] 
ProsTATE CANCEr
New answers prompt new questions regarding cell of origin
Angelo M. De Marzo, William G. Nelson, Charles J. Bieberich and Srinivasan Yegnasubramanian
Controversies remain regarding the precise cell type from which prostate cancers originate. in the last 2 years, two separate studies have arrived at apparently conflicting models for the cell type involved in prostate cancer initiation. However, these results are not mutually exclusive: there are potential solutions, and alternative views on the initiating cell derivation of prostate tumors also exist.
it has been suggested that tumor-initiating cells of solid tumors originate from primitive tissue-based stem cells, as these are cells which survive long enough to accumulate a series of genetic and epigenetic alterations, possess inherent self-renewal ability, and are able to differentiate into a number of resident cell types. research during the last few years has produced a great deal of information regarding the stem cell biology of prostatic epithelia and its association with cancer. in their study, wang et al. 6 used genetic lineage mapping in the mouse prostate and identified rare multipotent luminal cells that could generate both basal and luminal cells in vivo. these cells, designated castrationresistant nkx3.1-positive cells, developed into adenocarcinoma when the tumor suppressor gene Pten was disrupted. Conversely, Goldstein et al. 3 used gene transfer into isolated human prostate cells and found that basal cells which expressed low or absent levels of the androgen receptor could be tumor-initiating cells, but that androgenreceptor-positive luminal cells could not. NEws & viEws lack of basal cells-a hallmark of the human disease. 3 in both studies, the authors suggest that a tissue stem cell is the cell of origin for prostate cancer, but in each case a different tissue stem cell was identified as the tumor-initiating cell.
How can these two disparate conclusions be reconciled? neither group claims that the cell type that they identified is the exclusive stem cell in the prostate, nor that it is the only tumor-initiating cell. Perhaps both cell types could be active in the prostate and produce tumors with different biological properties. 1, 2, 5 it is also interesting to consider how these findings fit with our knowledge of the human disease. numerous observations indicate that in high-grade Pin, only luminal-like cells possess the somatic genomic changes found in invasive carcinomas. 7 silencing of the GSTP1 promoter by CpG island hypermethylation occurs in approximately 90% of prostatic carcinomas and around 70% of Pin. in Pin, only the androgen-receptorpositive luminal cells lack GSTP1 protein. Furthermore, androgen-receptor-positive luminal cells are the only cells in Pin in which somatic telomere shortening (which can lead to chromosomal instability) occurs. tmPrss2-erG rearrangements, resulting in erG mrna and protein overexpression, occur in around 50% of prostatic carcinomas; and in erG-positive Pin lesions it is only the androgen-receptor-positive luminal cells which stain positively for erG protein. 8 the oncogenic transcription factor mYC is also overexpressed in most Pin lesions in the androgen-receptorpositive luminal compartment. 7 thus, while basal cells which are low or negative for the androgen receptor may be stem cells they do not contain the molecular genetic and epigenetic 'hits' which are characteristic of Pin or prostate adenocarcinoma, even within basal compart ments of Pin lesions. alternatively, it may be that such genetic and epigenetic changes have thus far eluded detection.
Perhaps key carcinogenic hits do occur in basal cells, but the consequences manifest only when the cells lose basal cell features-for example, expression of p63-and undergo differentiation to luminal cells. this could explain the lack of basal cells seen in prostatic carcinoma. analogy to some leukemias suggests that a proliferative or survival advantage from such hits would be expected to produce an expansion of this precursor basal cell population. while this expansion was found in one mouse model of prostate cancer, 1 an expansion of basal cells in prostate cancer or Pin has not been identified in humans. another possi bility is that when oncogenic stress occurs in basal cells, they rapidly differentiate into luminal-like cells which appear neo plastic, leaving no trace of their previous basal state. 1 ,2 regardless of the cell in which the initial oncogenic or tumor suppressive hits occur, some of the resulting neoplastic luminal-like cells do not fully differ entiate to become 'postmitotic' . recently, plausible mechanisms responsible for this differ entiation block have arisen, and over expression of mYC or erG both seem capable of inducing such a block. [7] [8] [9] there are alternative views to the notion that tissue stem cells are the sole direct target cells of tumor initiation. Data have accumulated indicating that certain tumor types do not originate from multipotent tissue stem cells, but rather from differentiated progenitor cells that co-opt self-renewal programs from the tissue stem cells. it has been suggested that such cells are responsible for initiating development of prostate tumors. For example, the human prostate contains regions of focal atrophy-often associated with variable degrees of inflammation-in which many of the atrophic luminal cells have an intermediate phenotype. 7 these focal atrophy lesions appear in the prostate in response to diverse carcinogenic insults, including exposures to dietary heterocyclic amines, estrogens, and various pathogens. Furthermore, these regions of expanded proliferating intermediate cells commonly show transitions to Pin and, at times, to adenocarcinoma, supporting the notion that neoplastic transformation may commence in intermediate cells. 7 Perhaps the focus thus far has been misdirected somewhat. recent findings indicate that four transcription factors (mYC, KlF4, oct4, and soX2) can reprogram fully differentiated cells into induced pluripotent stem cells. thus, it is now plausible that even mature differentiated postmitotic prostatic luminal cells that lack inherent self-renewal capabilities could be 'reprogrammed' by oncogenic pressure into tumor-initiating Pin cells. 7 in addition, the self-renewal programs co-opted by the transformed cell need not originate in cognate tissue stem cells. rather, certain oncoproteins may induce aberrant self-renewal programs foreign to the tissue stem cells, such as those found in embryonic stem cells. 10 in the prostate, the oncogenic activation could occur in any of the cell compartments , although we favor one of the luminal cell types (Figure 1) . the resultant tumor-initiating cell would probably express a phenotype reminiscent of a luminal cell, but with no precisely matched NEws & viEws 'normal cell' . the intense research activity in this field should help resolve these apparent disagreements, which will undoubtedly produce a deeper under standing of the biology of prostate cancer.
